last
year
known
broadspectrum
agent
tiloron
dihydrochlorid
tiloron
last
year
major
ebola
viru
outbreak
africa
zika
viru
brazil
current
midst
novel
coronaviru
sever
acut
respiratori
syndrom
coronaviru
current
spread
global
china
time
write
virus
abil
rapidli
spread
addit
countri
origin
locat
creat
massiv
financi
impact
overal
morbid
viru
outbreak
gener
pale
comparison
common
viral
infect
influenza
hiv
hbv
kill
order
magnitud
annual
newer
virus
howev
attract
signific
attent
lack
avail
treatment
fear
unknown
also
indic
need
broader
spectrum
antivir
use
new
emerg
viru
affect
human
health
one
promis
drug
tiloron
dihydrochlorid
tiloron
diethylamino
ethoxi
smallmolecul
da
oral
bioavail
fig
drug
typic
use
dihydrochlorid
salt
form
yelloworang
color
tiloron
origin
synthes
develop
pharmaceut
compani
merrel
dow
part
sanofi
synthesi
improv
upon
recent
year
tiloron
current
use
clinic
antivir
sever
countri
outsid
usa
sold
trade
name
approv
use
russia
sever
viral
diseas
indic
influenza
acut
respiratori
viral
infect
viral
hepat
viral
enceph
myeliti
other
includ
list
vital
essenti
medicin
russian
feder
tiloron
also
regist
human
use
ukrain
kazakhstan
belaru
armenia
georgia
kyrgyzstan
moldova
turkmenistan
uzbekistan
antivir
immunomodul
medic
russia
tiloron
also
avail
counter
adult
child
age
dosag
tiloron
track
record
safe
use
children
adult
year
prophylaxi
treatment
viral
diseas
drug
produc
manufactur
kiloton
kg
scale
produc
low
cost
per
dose
base
current
list
price
vivo
efficaci
studi
literatur
support
possibl
use
tiloron
broad
array
infect
includ
influenza
influenza
b
herp
simplex
viru
west
nile
viru
mengo
viru
semliki
forest
viru
vesicular
stomat
viru
encephalomyocard
viru
recent
human
coronavirus
includ
merscov
tabl
human
clinic
studi
outsid
us
evalu
tiloron
treatment
acut
respiratori
viral
infect
arvi
demonstr
significantli
improv
patient
outcom
drug
also
show
prophylact
efficaci
respiratori
tract
infect
human
tiloron
undergon
sever
clinic
trial
publish
russian
journal
besid
track
record
use
russia
neighbor
countri
tiloron
never
evalu
test
safeti
efficaci
studi
meet
current
ich
fda
guidelin
regul
previou
nonclin
data
readili
avail
despit
histori
use
viral
diseas
activ
ebov
discov
use
machinelearn
comput
model
train
vitro
antiebola
screen
data
train
data
gener
larg
collabor
drugrepurpos
program
identifi
multipl
class
ebola
inhibitor
vitro
vivo
activ
model
predict
ebola
inhibitori
activ
tiloron
test
use
vitro
antiebola
assay
activ
tiloron
gave
effect
concentr
ec
assay
nm
tabl
ii
make
one
potent
smallmolecul
inhibitor
ebov
report
time
seri
toxic
pharmacokinet
studi
compound
test
mous
model
ebov
infect
associ
surviv
mous
ebov
efficaci
studi
three
differ
dose
comparison
vehicletr
group
surviv
interestingli
tiloron
either
compar
significantli
reduc
surviv
rate
compar
vehicl
guinea
pig
infect
ebov
result
led
us
broadli
profil
antivir
spectrum
activ
tiloron
tabl
ii
recent
data
suggest
tiloron
use
marburg
marv
well
chikungunya
viru
chik
middl
eastern
respiratori
syndrom
coronaviru
merscov
tabl
ii
make
potenti
broadspectrum
class
antivir
therapeut
demonstr
efficaci
preclin
anim
diseas
model
divers
viral
famili
includ
filoviru
hepadnaviru
human
herpesviru
orthomyxoviru
picornaviru
alphaviru
rhabdoviru
flaviviru
tiloron
initi
identifi
induc
interferon
oral
administr
discoveri
tiloron
follow
public
describ
abil
induc
interferon
ifn
possibl
antivir
mechan
tiloron
water
solubl
highli
permeabl
abl
penetr
bloodbrain
barrier
suggest
could
access
site
bodi
virus
might
hide
surpris
differ
antiebov
assay
perform
hela
cell
vero
cell
tabl
ii
initi
indic
may
due
latter
ifndefici
unlik
normal
mammalian
cell
may
respond
tiloron
manner
hela
cell
given
report
activ
tiloron
induc
ifn
differenti
antivir
activ
data
support
hypothesi
antivir
activ
tiloron
like
deriv
activ
host
innat
immun
pathway
interestingli
fact
vitro
antivir
activ
observ
merscov
chikv
vero
cell
suggest
virus
affect
differ
innat
immun
pathway
tiloron
multipl
target
contribut
overal
antivir
activ
mice
treat
tiloron
maebov
challeng
unchalleng
anim
numer
cytokin
chemokin
increas
significantli
unchalleng
mice
inject
tiloron
vs
vehicl
group
show
significantli
higher
level
eotaxin
rant
rant
multipl
case
unchalleng
tiloron
mice
significantli
higher
respons
mani
cytokin
chemokin
compar
maebovchalleng
group
administ
tiloron
case
eotaxin
rant
tiloron
also
shown
increas
vivo
secret
tnfa
macrophag
balbc
mice
found
refer
refer
explicitli
side
effect
tiloron
product
proinflammatori
cytokin
respons
drug
treatment
may
exacerb
clinic
symptom
viral
infect
result
cytokin
storm
influenza
antivir
efficaci
tiloron
observ
lack
vitro
antiebov
potenc
ifndefici
cell
line
led
us
hypothes
drug
may
work
activ
specif
innat
immun
system
pathway
suppress
viral
replic
one
candid
target
riglik
receptor
rlr
signal
pathway
recogn
intracellular
viral
rna
induc
cellular
respons
lead
induct
ifn
fig
exact
mechan
yet
proven
sever
piec
data
support
hypothesi
activ
rlr
signal
pathway
lead
ifn
product
wellknown
activ
tiloron
tiloron
caus
rapid
increas
mitochondri
potenti
minut
may
reflect
activ
direct
downstream
signal
partner
rigi
call
mitochondri
antivir
signal
protein
mav
rlr
signal
mav
protein
shown
critic
mediat
viral
replic
mice
vitro
bind
data
show
tiloron
directli
bind
human
rigi
though
weakli
assay
perform
simpl
buffer
cellular
compon
fig
lysosomotrop
amin
diffus
freeli
rapidli
across
membran
acid
cytoplasm
organel
unproton
form
enter
acid
environ
becom
proton
halt
free
diffus
caus
substanti
accumul
lysosomotrop
amin
concentr
organel
increas
concentr
tiloron
also
found
increas
lysosom
ph
inhibit
atpdepend
acidif
also
recent
confirm
tiloron
lysosomotrop
ic
par
well
known
lysosomotrop
compound
chloroquin
fig
other
shown
tiloron
induc
glycosaminoglycan
storag
separ
tiloron
induc
secret
lysosom
enzym
lysosomotrop
mechan
may
also
import
role
tiloron
block
viral
entri
cation
amphiphil
drug
propos
recent
use
start
point
broad
spectrum
antivir
recent
speci
comparison
metabol
tiloron
demonstr
ndeethyl
monooxygen
higher
guinea
pig
rel
mous
human
speciesliv
microsom
stabil
relationship
increas
order
guinea
pig
nonhuman
primat
mous
follow
human
differ
metabol
stabil
speci
could
also
account
differ
efficaci
observ
mous
guinea
pig
model
ebov
treat
tiloron
wherea
saw
efficaci
mous
appar
guinea
pig
may
due
metabol
stabil
differ
mani
antivir
drug
sever
individu
viral
diseas
eg
hiv
hbv
influenza
etc
current
broadspectrum
antivir
approv
usa
contrast
tiloron
wide
use
outsid
usa
sever
decad
recent
data
suggest
efficaci
anim
model
ebov
infect
addit
vitro
activ
sever
group
support
use
molecul
broadspectrum
treatment
variou
viral
infect
preclin
data
around
compound
avail
data
allow
candid
product
profil
gener
tabl
iii
document
serv
guid
futur
develop
effort
expect
chang
addit
occur
addit
data
interact
fda
regulatori
agenc
preliminari
data
character
activ
properti
tiloron
alreadi
support
mani
target
paramet
need
move
forward
broadspectrum
antivir
sever
recent
articl
focus
repurpos
class
drug
order
identifi
novel
broad
spectrum
antivir
found
impact
viral
entri
addit
broad
spectrum
antivir
drug
approv
russia
elsewher
may
also
worthi
assess
global
arbidol
triazavirin
cycloferon
kagocel
tiloron
alreadi
antivir
drug
bare
begun
exploit
sinc
develop
year
ago
recent
discoveri
reveal
littl
potenti
antivir
mechan
sever
addit
activ
compound
therefor
ripe
widespread
test
product
descript
tiloron
dihydrochlorid
oral
use
form
tablet
tiloron
dihydrochlorid
inhibitor
viral
replic
mammalian
host
cell
activ
innat
immun
signal
pathway
one
pathway
may
rigisign
pathway
respons
sens
intracellular
viral
rna
activ
cellular
antivir
respons
role
may
via
lysosomotrop
activ
could
impact
viral
entri
antivir
activ
ebov
viral
replic
ec
tablet
suppli
singl
dosag
strength
packag
maxim
stabil
highhumid
warm
temperatur
environ
